Benefits
Menopausal Symptom Relief
The Sharif 2019 placebo-controlled RCT (n=200, 8 weeks, 1,000 mg/day) showed significant reduction in total menopausal symptom score in postmenopausal women. The Asama 2018 Japanese RCT (n=42, 800 mg/day enzyme-treated RJ, 12 weeks) showed significant improvement in anxiety and backache/low back pain scores. The 2025 systematic review and meta-analysis supports modest benefit for menopausal symptoms.
Possible Mental Wellness Effects
Some trials report improvements in anxiety, mood, and quality of life — potentially relevant for menopausal women experiencing perimenopausal mood changes. Effect sizes are small to moderate and trial heterogeneity is high.
Possible Lipid Profile Effects
Some trials report modest reductions in total cholesterol and LDL, with potential HDL increases. Evidence is limited and inconsistent; effect sizes are small. Not a substitute for proven lipid-lowering interventions.
Traditional Use for Vitality and Fertility
Royal jelly has been used traditionally as a 'health tonic' and fertility aid. Some animal studies suggest effects on ovarian function and sperm parameters, but rigorous human fertility RCTs are limited.
Skin Health (Limited Evidence)
Royal jelly is included in many topical and oral skin products. 10-HDA shows some effects on skin biology in vitro. Clinical evidence specifically for skin appearance/aging is preliminary.
Mechanism of action
Mild Estrogenic Activity
Some royal jelly components show weak estrogenic activity in vitro, potentially binding estrogen receptors at low affinity. This may underlie the menopausal symptom benefits — though effects are far weaker than estrogens or even traditional phytoestrogens (genistein, daidzein).
10-Hydroxy-2-Decenoic Acid (10-HDA) Bioactivity
10-HDA is a unique fatty acid found only in royal jelly. It shows multiple biological activities in vitro: antibacterial, anti-inflammatory, immunomodulatory, and weak estrogen receptor binding. It is often used as a quality marker for royal jelly products.
Major Royal Jelly Proteins (MRJPs)
MRJPs (especially MRJP1, also called royalactin) constitute ~80% of royal jelly proteins. They have antimicrobial, antioxidant, and immune-modulating activities in vitro. MRJP3 is also a major allergen — implicated in cross-reactivity with honeycomb in anaphylaxis cases.
Antioxidant Activity
Royal jelly contains phenolic compounds, flavonoids, and unique fatty acids with antioxidant activity. Some clinical trials show modest reductions in oxidative stress markers.
Immunomodulatory Effects
Royal jelly modulates cytokine profiles in vitro — generally toward an anti-inflammatory pattern. The clinical relevance for autoimmune conditions or general immune health is not well-established.
Clinical trials
Double-blind, randomized, placebo-controlled trial. 1,000 mg royal jelly capsules daily or placebo for 8 weeks in postmenopausal women aged 45-60 in Bandar Abbas, Iran. Conducted June-November 2018. (Sharif, Darsareh 2019, Complement Ther Clin Pract)
200 postmenopausal women aged 45-60.
Mean baseline menopausal score did not differ between groups. After 8 weeks, the menopausal symptom score reduced significantly in the royal jelly group whereas reduction was not significant in the placebo group. Authors concluded daily 1,000 mg royal jelly was effective for alleviating menopausal symptoms. Further confirmatory research recommended.
Double-blind, randomized, placebo-controlled trial. 800 mg/day enzyme-treated royal jelly powder vs. placebo (800 mg dextrin) for 12 weeks. Menopausal symptoms assessed every 4 weeks via Japanese-women-specific questionnaire. (Asama, Hiraoka, Tashiro et al. 2018, Evid Based Complement Alternat Med)
42 healthy Japanese postmenopausal women (21 per arm). 12-week intervention.
Significant differences in anxiety score (p=0.046) and backache/low back pain score (p=0.040) between RJ and placebo at 12 weeks. No significant differences at 4 weeks — effects required time to develop. No side effects observed. Important: Japanese menopausal symptoms differ from Western patterns (more neck stiffness/back pain, fewer hot flashes) — may explain the specific symptom domain effects.
Systematic review and meta-analysis of randomized controlled trials evaluating royal jelly for management of postmenopausal symptoms. (Multi-author 2025, Menopause)
6 RCTs, 471 postmenopausal women (from 281 studies identified).
Royal jelly supplementation significantly improved postmenopausal symptoms vs. placebo. Standardized mean difference (SMD) = 0.73, 95% CI 0.50-0.96, p<0.00001, I²=0%, moderate-quality evidence (per GRADE). Authors concluded RJ may offer a promising nonhormone option for managing menopausal symptoms, particularly for women who cannot use hormone therapy. Search through May 2025; published online December 2025 / print issue April 2026.
Case series and immunologic investigation of seven subjects with asthma and/or anaphylaxis following royal jelly ingestion. Skin-prick tests, IgE immunoassays, and protein blotting performed. (Thien, Leung, Baldo, Weiner, Plomley, Czarny 1996, Clin Exp Allergy)
7 subjects who developed asthma and (in some cases) anaphylaxis after royal jelly ingestion. 6 of 7 female; all atopic with positive grass pollen reactions. Three of seven also tested with bee venom — negative reactions.
Skin-prick tests, immunoassays, and protein blotting confirmed IgE-mediated true hypersensitivity reactions. 18 different IgE-binding components detected on royal jelly protein blots; one ~55 kDa component bound by all reactive sera. Notably, 38% of bee-venom-allergic subjects (out of 63 sera tested) and 52% of subjects with inhalant/food allergies (out of 75 sera) showed IgE reactivity to royal jelly proteins — indicating cross-reactivity with common environmental allergens. Established the medical recognition of royal jelly as a potentially serious anaphylaxis trigger in atopic individuals.
Original report of five cases of royal jelly-induced asthma and anaphylaxis. (Leung, Thien, Baldo, Czarny 1995, J Allergy Clin Immunol)
5 atopic patients with reactions to royal jelly.
Documents IgE-mediated hypersensitivity reactions to royal jelly in atopic individuals. Established the medical recognition of royal jelly as a potential anaphylaxis trigger — particularly relevant given growing supplemental use. Cross-reactivity with other inhalant allergens may explain reactions on first ingestion.
About this ingredient
Royal jelly is the milky white-to-yellow secretion produced from the hypopharyngeal and mandibular glands of nurse honeybees (Apis mellifera) and fed exclusively to queen bee larvae throughout development and to adult queens throughout their lives. Composition: ~60-70% water, 12-15% protein, 10-16% carbohydrates, 3-6% lipids, plus vitamins (B-complex), minerals, and unique bioactives. Principal bioactives include Major Royal Jelly Proteins (MRJP1-9, with MRJP1/royalactin being most abundant), 10-hydroxy-2-decenoic acid (10-HDA, a unique signature fatty acid), and various sterols and antimicrobial peptides.
EVIDENCE: Modest support for menopausal symptom improvement (Sharif 2019, Asama 2018, 2025 meta-analysis). Mechanisms include mild estrogenic activity and antioxidant effects. Most other claims (anti-aging, fertility, immune support) are based on traditional use and animal/in vitro data.
SAFETY: **CRITICAL ALLERGY WARNING** — Royal jelly can trigger severe asthma, anaphylaxis, and IgE-mediated hypersensitivity reactions, particularly in atopic individuals (asthma, allergic rhinitis, eczema, food allergies). Anaphylaxis can occur on first exposure via cross-reactivity with environmental allergens. AVOID if you have asthma, multiple allergies, bee/honey allergy, or atopic dermatitis.
Pregnancy/lactation: avoid due to insufficient safety data. NOT recommended as a first-line approach for menopausal symptoms — discuss with a physician.